Skip to main content

Advertisement

Table 4 Treatment-related adverse events

From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

  Any grade Grade 3 Grade 4
Hematologic
 Neutropenia 23 (71.9) 6 (18.8) 7 (21.9)
 Anemia 7 (21.9) 1 (3.1) 0
 Thrombopenia 5 (15.6) 2 (6.3) 0
 Febrile Neutropenia 1 (3.1) 1 (3.1) 0
Nonhematologic
 Fatigue 16 (50.0) 4 (12.5) 0
 Alopecia 22 (68.7) N/A
 Peripheral neuropathy 15 (46.9) 4 (12.5) 0
 Arthralgia 4 (12.6) 0 0
 Constipation 7 (21.9) 1 (3.1) 0
 Diarrhea 2 (6.2) 0 0
 Nausea 8 (25.0) 0 0
 Vomitting 1 (3.1) 0 0
 Stomatitis 9 (28.1) 2 (6.3) 0